预约演示
更新于：2025-05-31
Acetaminophen/Oxycodone Hydrochloride
氨酚羟考酮
更新于：2025-05-31
概要
基本信息
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 中国 (2004-01-21), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C18H22ClNO4 |
InChIKeyMUZQPDBAOYKNLO-RKXJKUSZSA-N |
CAS号124-90-3 |
查看全部结构式(2)
关联
39
项与 氨酚羟考酮 相关的临床试验CTR20250869
氨酚羟考酮缓释片用于治疗术后中重度疼痛的有效性和安全性的多中心、随机、双盲、阳性药和安慰剂对照临床试验
CTR20242166
比较氨酚羟考酮缓释片与氨酚羟考酮片的药代动力学特征并评估食物对氨酚羟考酮缓释片药代动力学的影响研究
CTR20241203
氨酚羟考酮片人体生物等效性试验
100 项与 氨酚羟考酮 相关的临床结果
登录后查看更多信息
100 项与 氨酚羟考酮 相关的转化医学
登录后查看更多信息
100 项与 氨酚羟考酮 相关的专利（医药）
登录后查看更多信息
79
项与 氨酚羟考酮 相关的文献（医药）2024-06-01Drug and alcohol dependence reports
Xylazine awareness, desire, use and exposure: Preliminary findings from the Rhode Island community-based drug checking cohort study
Article
作者: Tardif, Jessica ; Park, Ju Nyeong ; Ujeneza, Merci ; Serafinski, Rachel ; Krotulski, Alex J ; Grossman, Elyse R ; Badea, Adina ; Green, Traci C ; McKenzie, Michelle
Background:
Xylazine is an ⍺2 adrenergic receptor agonist and a veterinary sedative that can cause severe health complications yet interventions to detect and treat human exposure remain underdeveloped. Community-based drug checking services (DCS) involve the testing of small amounts of drugs to increase community knowledge of unregulated supplies and decrease harms. This study characterized xylazine awareness, desire, use and exposure among people who use drugs (PWUD) in Rhode Island, US.
Methods:
We analyzed data from an ongoing PWUD cohort study. In 2023, 125 PWUD were enrolled and surveyed. Using point-of-care Fourier Transform infrared spectroscopy (FTIR-S), we tested a drug sample from each participant onsite and confirmed the results offsite at a laboratory. Results were conveyed in real-time, along with harm reduction education, referrals to resources and care.
Results:
Virtually all participants (99.2 %) wanted to avoid xylazine exposure. Half (51.2 %) knew what xylazine was, and a quarter (26.1 %) suspected previous exposure. Xylazine exposure was primarily surmised through sedating (45.2 %) and ulcerative (29.0 %) effects. Only 8.8 % of participants submitted a sample that they expected to contain xylazine. Xylazine was detected in 14.5 % of samples using FTIR-S and in 21.4 % of samples using a dual laboratory approach of gas chromatography mass spectrometry (GC-MS) and liquid chromatography quadrupole-time-of-flight mass spectrometry (LC-QTOF-MS). Participants thought that these xylazine-positive samples were fentanyl (78.3 %), heroin (13.0 %), or Percocet® (8.7 %).
Conclusion:
Implementing point-of-care DCS at harm reduction organizations could be useful in rapidly increasing xylazine awareness and engaging at-risk individuals in prevention, harm reduction, treatment, and rapid care for xylazine-related wounds.
2023-02-01Health economics
Recreational marijuana laws and the misuse of prescription opioids: Evidence from National Survey on Drug Use and Health microdata
Article
作者: McClellan, Chandler ; Ali, Mir M. ; Mutter, Ryan ; Rees, Daniel I.
Abstract:
Several studies have concluded that legalizing medical marijuana can reduce deaths from opioid overdoses. Drawing on micro data from the National Survey on Drug Use and Health, a survey uniquely suited to assessing patterns of substance use, we examine the relationship between recreational marijuana laws (RMLs) and the misuse of prescription opioids. Using a standard difference‐in‐differences (DD) regression model, we find that RML adoption reduces the likelihood of frequently misusing prescription opioids such as OxyContin, Percocet, and Vicodin. However, using a two‐stage procedure designed to account for staggered treatment and dynamic effects, the DD estimate of relationship between RML adoption and the likelihood of frequently misusing prescription opioids becomes positive. Although event study estimates suggest that RML adoption leads to a decrease in the frequency of prescription opioid abuse, this effect appears to dissipate after only 2 or 3 years.
2022-03-01Global spine journal3区 · 医学
Variability in Opioid Prescription Following Primary Single-Level Lumbar Microdiscectomy
3区 · 医学
ArticleOA
作者: Roberto, Rolando ; Agatstein, Lauren ; Javidan, Yashar ; Le, Hai ; Barber, Joshua ; Phan, Eileen ; Klineberg, Eric
Study Design::
Retrospective case series.
Objectives::
To evaluate the variability in opioid prescription following primary single-level lumbar microdiscectomy.
Methods::
We retrospectively reviewed consecutive patients who underwent primary single-level lumbar microdiscectomy. Only opioid-naïve patients ≥18 years old were included. Patients who had revision microdiscectomy, multilevel decompression, and/or any complication requiring prolonged hospital stay (>2 days) were excluded. The primary outcomes were the maximum daily dosage of opioids prescribed in morphine milligram equivalents (MME) and the number of pills prescribed (equivalent to 5 mg hydrocodone).
Results::
Between 2014 and 2019, 169 patients (90 men, 79 women) met inclusion criteria, with a mean age of 46.9 years. Surgery resulted in a statistically significant improvement in VAS (Visual Analogue Scale) score (6.4 to 2.5, P < .01). At discharge, 8 patients (4.7%) did not receive any opioid prescription. Of the remaining 161 patients, 1 patient (0.01%) received hydromorphone, 30 (18.6%) Percocet, 43 (26.7%) oxycodone, and 87 Norco (54.0%). The length of opioid prescription was 6.7 days. The maximum daily dosage of opioids prescribed was 70.4 MME (SD 32.1). The total number of pills prescribed was 89.4 (SD 54.7). Twenty-five patients (15.5%) received a refill prescription. Multivariate analysis demonstrated the operating service, prescriber, and hospital admission were statistically significant predictors of maximum daily MME. The prescriber and hospital admission were statistically significant predictors of total number of pills prescribed.
Conclusions::
We found significant variability in opioid prescription following primary single-level lumbar microdiscectomy. For standard spinal procedures like lumbar microdiscectomy, opioid-prescribing guidelines should be established to standardize postoperative pain management.
100 项与 氨酚羟考酮 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 急性疼痛 | 美国 | 2014-03-11 | |
| 疼痛 | 中国 | 2004-01-21 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 中度疼痛 | 临床3期 | 中国 | 2024-02-18 | |
| 重度疼痛 | 临床3期 | 中国 | 2024-02-18 | |
| 拇囊炎 | 临床3期 | 美国 | 2011-11-01 | |
| 术后疼痛 | 临床3期 | 美国 | 2011-11-01 | |
| 腰痛 | 临床3期 | 美国 | 2011-09-20 | |
| 骨关节炎 | 临床3期 | 美国 | 2011-09-20 | |
| 慢性疼痛 | 临床1期 | 中国 | 2022-11-21 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | - | 100 | (Acetaminophen Along With a Reduced Quantity of Percocet) | 廠窪壓鏇鹽製衊範齋膚(壓憲鏇膚艱遞鬱襯繭廠) = 構鹽簾築餘淵鏇襯艱築 窪觸糧範繭齋選觸鹹餘 (構積夢簾憲築網範積遞, 1.52) 更多 | - | 2021-01-07 | |
(Percocet Only) | 廠窪壓鏇鹽製衊範齋膚(壓憲鏇膚艱遞鬱襯繭廠) = 醖願鹽構願鏇鬱獵獵齋 窪觸糧範繭齋選觸鹹餘 (構積夢簾憲築網範積遞, 1.55) 更多 | ||||||
临床3期 | 376 | 築夢製廠鏇觸襯構窪廠 = 餘糧鹹窪遞糧構築鹹遞 憲艱醖壓範獵簾蓋簾淵 (廠醖憲艱淵齋築鬱鏇願, 淵襯繭壓顧襯壓觸範醖 ~ 範獵製顧鏇網齋鏇憲蓋) 更多 | - | 2020-09-17 | |||
临床4期 | 23 | 蓋膚襯願衊遞醖餘襯淵(鑰鹹蓋夢製觸衊醖鹽餘) = 廠願壓製簾壓簾廠遞醖 窪憲襯鏇願繭膚餘憲獵 (鹹繭遞淵糧夢齋鹽鑰獵, 鹽觸積襯膚鹹齋鏇壓製 ~ 獵窪繭鹹衊窪壓願壓繭) 更多 | - | 2020-01-22 | |||
N/A | 23 | Knee Brace and Crutches+Percocet (No Injection) | 鑰艱衊顧窪蓋鹽顧獵齋(鹽獵壓範築遞鹽觸蓋鹽) = 願膚憲鏇窪觸艱鑰獵願 鑰選憲顧鑰簾衊鏇觸窪 (簾選膚範鹽獵憲獵夢鹹, 衊製觸膚獵窪簾構築鹹 ~ 範窪齋衊夢網醖獵壓積) 更多 | - | 2017-12-14 | ||
鑰艱衊顧窪蓋鹽顧獵齋(鹽獵壓範築遞鹽觸蓋鹽) = 襯蓋鏇顧鬱觸廠壓餘壓 鑰選憲顧鑰簾衊鏇觸窪 (簾選膚範鹽獵憲獵夢鹹, 觸壓遞襯構襯衊鏇繭衊 ~ 膚廠繭鹽餘艱襯簾餘鹽) 更多 | |||||||
临床4期 | 115 | (Femoral Nerve Block) | 夢築鏇窪壓餘選願製願(鹽襯鹹選築願淵鬱鬱鏇) = 觸廠顧繭製齋鑰糧簾膚 遞膚製憲願齋壓觸淵鬱 (憲鬱鹽鏇鹽壓餘構衊衊, 1.8) 更多 | - | 2017-05-31 | ||
(Adductor Canal Block) | 夢築鏇窪壓餘選願製願(鹽襯鹹選築願淵鬱鬱鏇) = 簾糧網顧醖構蓋選襯選 遞膚製憲願齋壓觸淵鬱 (憲鬱鹽鏇鹽壓餘構衊衊, 2.8) 更多 | ||||||
临床3期 | 329 | (COV795) | 淵觸廠築積膚襯膚襯製(膚鹽艱選鹹繭積繭繭築) = 鏇築廠鬱選獵獵範夢淵 淵選鏇醖觸醖衊夢衊製 (鑰願願壓鏇齋簾鹹網醖, 7.64) 更多 | - | 2014-07-02 | ||
Placebo (Placebo) | 淵觸廠築積膚襯膚襯製(膚鹽艱選鹹繭積繭繭築) = 築襯範選憲鏇醖網蓋餘 淵選鏇醖觸醖衊夢衊製 (鑰願願壓鏇齋簾鹹網醖, 7.6) 更多 | ||||||
临床4期 | 84 | (VESIcare + Narcotic Painkiller) | 襯遞網範選醖遞衊艱獵(淵網願淵鬱壓衊鹽鬱蓋) = 繭齋顧繭構廠餘製襯憲 窪廠糧觸淵憲網夢獵獵 (觸選獵膚繭範簾壓積憲, 積膚願製網積壓餘積衊 ~ 夢鹽範襯範艱襯夢觸簾) 更多 | - | 2012-08-22 | ||
(Narcotic Painkiller) | 襯遞網範選醖遞衊艱獵(淵網願淵鬱壓衊鹽鬱蓋) = 獵夢鹽願顧鬱範鹽願窪 窪廠糧觸淵憲網夢獵獵 (觸選獵膚繭範簾壓積憲, 夢遞廠憲齋襯鏇願壓獵 ~ 鑰獵襯窪構積積願網觸) 更多 | ||||||
N/A | 124 | Acetaminophen+Oxycodone (Oral Narcotic Group) | 餘夢繭憲築構糧淵蓋築(獵窪鑰鬱壓製範衊膚蓋) = 積壓網積齋糧襯鹽簾積 廠積鬱鑰顧範餘選鬱襯 (顧顧簾壓醖積積網網艱, 3.45) 更多 | - | 2012-06-13 | ||
Bupivacaine (Bupivacaine Group) | 餘夢繭憲築構糧淵蓋築(獵窪鑰鬱壓製範衊膚蓋) = 鑰遞選觸窪顧簾廠糧鹽 廠積鬱鑰顧範餘選鬱襯 (顧顧簾壓醖積積網網艱, 3.28) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用